US · Healthcare · Biotechnology
EPS came in at -0.05 against a street estimate of -0.07 — a beat of 30.4%.
Analysts rate Sellas Life Sciences Group Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $27.50.
| Fund | Stake |
|---|---|
| BlackRock Inc | 6.20% |
| State Street Corp | 4.27% |
| Vanguard Capital Management, LLC | 3.83% |
| Geode Capital Management, LLC | 1.99% |
| Marshall Wace Asset Management Ltd | 1.04% |
| JONES FINANCIAL COMPANIES LLLP | 0.85% |
| Vanguard Portfolio Management, LLC | 0.74% |
| Morgan Stanley - Brokerage Accounts | 0.68% |
| Document | Date |
|---|---|
| Results announced · Q3 2026 | 2026-07-27 |
| Board / officer change · Q2 2026 | 2026-06-25 |
| Shareholder vote results · Q2 2026 | 2026-06-18 |
| Company announcement · Q2 2026 | 2026-06-02 |
| Quarterly report · Q1 2026 | 2026-05-12 |
| Proxy statement · Q2 2026 | 2026-04-23 |
| Annual report FY2025 | 2026-03-19 |
| Quarterly report · Q3 2025 | 2025-11-12 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Sellas Life Sciences Group Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.